We are live on
!
Find out more
OP
Omni Partners Portfolio holdings
AUM
$2.03B
1-Year Est. Return
126.33%
This Fund
S&P 500
This Quarter
Est. Return
+7.3%
1 Year Est. Return
+126.33%
3 Year Est. Return
+411.65%
5 Year Est. Return
+1,549.93%
10 Year Est. Return
–
AUM
$580M
AUM Growth
-$204M
(-26%)
Cap. Flow
-$218M
Cap. Flow
% of AUM
-37.61%
Top 10 Holdings %
Top 10 Hldgs %
94.76%
Holding
43
New
19
Increased
4
Reduced
1
Closed
19
Top Buys
| 1 |
NXP Semiconductors
NXPI
|
+$254M |
| 2 |
CPN
Calpine Corporation
CPN
|
+$29.6M |
| 3 |
CAVM
Cavium, Inc.
CAVM
|
+$27.8M |
| 4 |
AAAP
Advanced Accelerator Applications S.A.
AAAP
|
+$23.6M |
| 5 |
AET
Aetna Inc
AET
|
+$12.6M |
Top Sells
| 1 |
KITE
Kite Pharma, Inc.
KITE
|
+$119M |
| 2 |
TWX
Time Warner Inc
TWX
|
+$92.6M |
| 3 |
RICE
Rice Energy Inc.
RICE
|
+$83.2M |
| 4 |
LVLT
Level 3 Communications Inc
LVLT
|
+$50.7M |
| 5 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$43.4M |
Sector Composition
| 1 | Technology | 66.02% |
| 2 | Utilities | 16.91% |
| 3 | Healthcare | 5.88% |
| 4 | Financials | 2.28% |
| 5 | Communication Services | 1.16% |
Similar funds
BUB
PAG
SBSB
PPCM
AAM
ALSV
TNB
FIB
Omni Partners's Q4 2017 Portfolio in Review
As of Q4 2017, Omni Partners held 43 positions worth $580M, down 26% from $783M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Omni Partners withdrew a net $218M in Q4 2017, closing 19 positions and reducing 1 holding. Its most notable exit was Kite Pharma, Inc., an estimated $119M position sold in full.
By sector, the portfolio is most concentrated in Technology at 66% of assets, up from 11% a quarter earlier, followed by Utilities and Healthcare.
Against the trend, Omni Partners opened a new position in Cavium, Inc. worth $30.1M.
- Omni Partners's largest Q4 2017 buy was Cavium, Inc.: 359,037 shares worth $30.1M.
- Omni Partners added most to NXP Semiconductors in Q4 2017, an estimated $254M increase.
- Omni Partners's biggest Q4 2017 reduction was Akorn Inc, cutting an estimated $1.43M.
- Omni Partners fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $119M.
- Omni Partners's ten largest holdings make up 95% of its $580M portfolio in Q4 2017.
- Omni Partners opened 19 new positions and closed 19 in Q4 2017.
- Omni Partners's portfolio value fell 26% quarter-over-quarter to $580M.
Based on Omni Partners's 13F filing for Q4 2017, filed 22 Jan 2018.